Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage

• Status: Completed
• Trial end date: 2004-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study to evaluate how recombinant tissue plasminogen activator (rt-PA) is utilized in patients with intraventricular hemorrhage (IVH). rt-PA is a drug that has been shown to dissolve blood, and may allow intraventricular catheters to be more effective for a longer period of time.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Treatments: Plasminogen; Tissue Plasminogen Activator

Criteria

Inclusion criteria:

• Intraventricular hemorrhage (IVH) confirmed by CT scan

• More than 12 hours post bleed

• Hematoma size stable by CT scan

• Post-IVH catheter CT scan

• Able to begin study within 24 hours of bleed

Exclusion criteria:

• Infratentorial bleed

• Supratentorial bleed greater than 30 cc

• Unclipped aneurysm suspected

• Arteriovenous malformation suspected

• Any severe, complicating illness (e.g., AIDS or DNR)

• Cardiovascular parameters that could confound study (e.g., myocardial infarction, pulmonary emboli, systemic fibrinolysis)

• Active internal bleeding

• Requirement for heparin doses greater than 10,000 U/day

• Concurrent coumadin

• Known allergy to rt-PA

• Pregnancy